- Home
- / Rein Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Rein Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.1
2024-10-29
Market Capitalization
$90.2 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 5.1M | 7.9M | 8.8M | 13.5M | 12.3M | 9.3M | 9.6M | 9.7M | 11.4M | 13.9M | 10.9M |
| Operating expense total | 12.9M | 18.2M | 23.0M | 31.9M | 30.0M | 20.5M | 26.6M | 27.6M | 28.1M | 21.9M | |
| Depreciation and amortization | 1.0K | ||||||||||
| EBIT | (12.9M) | (18.2M) | (23.0M) | (31.9M) | (30.0M) | (20.5M) | (26.6M) | (27.6M) | (16.3M) | (65.1M) | (50.6M) |
| Interest income | 13.0K | 46.0K | |||||||||
| Interest expense | 404.0K | 355.0K | 587.0K | ||||||||
| Income tax expense | (1.5M) | (712.0K) | |||||||||
| Net Income | (12.9M) | (18.1M) | (22.6M) | (31.5M) | (29.4M) | (21.2M) | (26.2M) | (27.3M) | (15.7M) | (62.9M) | (49.9M) |
| EPS | (6.0) | (3.0) | (3.5) | (2.0) |